CagriSema (cagrilintide + semaglutide) — UK research guide

What CagriSema is

CagriSema is Novo Nordisk's investigational fixed combination of two molecules: cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist). Both components are engineered for once-weekly subcutaneous administration. The combined molecule profile is at /peptides/cagrisema.

Evidence base

Phase 1b combination data (Lancet 2021) reported additive body-weight reduction with CagriSema versus semaglutide alone in the studied cohort. The phase 3 REDEFINE programme (REDEFINE 1 obesity, REDEFINE 2 type 2 diabetes) is in active readout cycle during 2024-2026.

UK regulatory status

CagriSema is investigational and is not licensed by the MHRA, EMA or FDA at the time of review. See research peptides and UK law for the regulatory framework around investigational compounds in the UK.

FAQs

What is CagriSema?

CagriSema is an investigational fixed combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist) developed by Novo Nordisk. The integrated mechanism engages two independent pathways implicated in satiety, gastric emptying and glycaemic control. It is investigational and not licensed for human therapeutic use anywhere at the time of review.

Is CagriSema licensed in the UK?

No. CagriSema is investigational and is not MHRA-licensed for any human therapeutic indication. Use is restricted to authorised clinical research.

How is CagriSema different from semaglutide alone?

CagriSema adds amylin signalling via cagrilintide to the GLP-1 receptor agonism of semaglutide. The combination is hypothesised to produce greater body-weight reduction than semaglutide alone; phase 3 confirmation (the REDEFINE programme) is in active readout cycle.

Procurement and supplier position

This page is educational and does not advertise, sell, supply, recommend or rank any supplier, compounder, online pharmacy or telehealth service for CagriSema or any of its components. As an investigational compound, CagriSema must not be used outside an authorised research setting.